Antivascular agents for non-small-cell lung cancer: Current status and future directions

Eitan Amir; Laszlo Mandoky; Fiona Blackhall; Nick Thatcher; Walter Klepetko; Hendrik Jan Ankersmit; Mir Ali Reza Hoda; Gyula Ostoros; Magdolna Dank; Balazs Dome

doi:10.1517/13543780903336050

Antivascular agents for non-small-cell lung cancer: Current status and future directions

Eitan Amir, Laszlo Mandoky, Fiona Blackhall, Nick Thatcher, Walter Klepetko, Hendrik Jan Ankersmit, Mir Ali Reza Hoda, Gyula Ostoros, Magdolna Dank, Balazs Dome

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. Objective: To summarize the current knowledge on antivascular therapy in patients with NSCLC. Method: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. Results/conclusion: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC. © 2009 Informa UK Ltd.

Original language	English
Pages (from-to)	1667-1686
Number of pages	19
Journal	Expert Opinion on Investigational Drugs
Volume	18
Issue number	11
DOIs	https://doi.org/10.1517/13543780903336050
Publication status	Published - Nov 2009

Keywords

Angiogenesis
Antivascular drug
Clinical trial
Non-small-cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/13543780903336050

Cite this

@article{a574ed59445f45acb029016421d12708,

title = "Antivascular agents for non-small-cell lung cancer: Current status and future directions",

abstract = "Background: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. Objective: To summarize the current knowledge on antivascular therapy in patients with NSCLC. Method: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. Results/conclusion: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC. {\textcopyright} 2009 Informa UK Ltd.",

keywords = "Angiogenesis, Antivascular drug, Clinical trial, Non-small-cell lung cancer",

author = "Eitan Amir and Laszlo Mandoky and Fiona Blackhall and Nick Thatcher and Walter Klepetko and Ankersmit, {Hendrik Jan} and {Reza Hoda}, {Mir Ali} and Gyula Ostoros and Magdolna Dank and Balazs Dome",

year = "2009",

month = nov,

doi = "10.1517/13543780903336050",

language = "English",

volume = "18",

pages = "1667--1686",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor & Francis",

number = "11",

}

TY - JOUR

T1 - Antivascular agents for non-small-cell lung cancer: Current status and future directions

AU - Amir, Eitan

AU - Mandoky, Laszlo

AU - Blackhall, Fiona

AU - Thatcher, Nick

AU - Klepetko, Walter

AU - Ankersmit, Hendrik Jan

AU - Reza Hoda, Mir Ali

AU - Ostoros, Gyula

AU - Dank, Magdolna

AU - Dome, Balazs

PY - 2009/11

Y1 - 2009/11

N2 - Background: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. Objective: To summarize the current knowledge on antivascular therapy in patients with NSCLC. Method: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. Results/conclusion: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC. © 2009 Informa UK Ltd.

AB - Background: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. Objective: To summarize the current knowledge on antivascular therapy in patients with NSCLC. Method: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. Results/conclusion: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC. © 2009 Informa UK Ltd.

KW - Angiogenesis

KW - Antivascular drug

KW - Clinical trial

KW - Non-small-cell lung cancer

U2 - 10.1517/13543780903336050

DO - 10.1517/13543780903336050

M3 - Article

C2 - 19877762

SN - 1354-3784

VL - 18

SP - 1667

EP - 1686

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 11

ER -

Antivascular agents for non-small-cell lung cancer: Current status and future directions

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this